Increase in Net Asset Value
Daxor's net assets increased from $34,010,384 in 2023 to $36,789,893 in 2024, reflecting a rise in net asset value per share from $7.08 to $7.25.
Significant Revenue Growth
Revenue increased by 116.5% year-on-year from 2024 versus 2023. In the first two months of 2025, revenue is over 100% higher than the same period in 2024.
Expansion of Clinical Partnerships
Daxor expanded into community hospital systems and formed strong relationships with various medical specialists, resulting in broader use of their technology.
FDA Submission for Next-Generation Analyzer
Daxor completed a multicenter study for its next-generation analyzer. They plan to resubmit a 510(k) application for a 90-day review.
Strategic Acquisitions
Daxor acquired rights to manufacture Volumex and Megatope and added Glofil to their product suite, expected to be cash flow positive and accretive.
Successful Funding and Contracts
Received a $2.5 million DoD contract and additional NIH grants totaling over $350,000.